Glutathione and the fading firewalls of the brain

research2693
Nov 11
9 min read

Inside our brains, millions of tiny power stations — neurones — work tirelessly to keep every thought, movement, and memory alive. But like any high-energy system, they produce by-products: unstable molecules that can damage delicate cell structures. Normally, the brain’s own defences sweep these threats away before they cause harm. At the centre of that defence lies glutathione (GSH) — a small but mighty antioxidant, often described as the body’s internal firewall (Kim et al., 2021).

Over the past decade, researchers have discovered that this antioxidant shield weakens in several neurodegenerative diseases. People with ALS/MND, Parkinson’s disease, and Alzheimer’s disease consistently show lower glutathione levels in both the brain and bloodstream (Kim et al., 2021; Chen et al., 2022). When that shield weakens, neurones become vulnerable to oxidative stress — essentially, the biological version of rust.

The deeper scientists look, the clearer it becomes that glutathione’s story is part chemistry, part mystery. Some findings point towards its protective role; others remind us how much we still have to learn. What emerges is a picture that is hopeful, but grounded in realism.

When the brain’s antioxidant defences wear thin

Every cell in the body runs a constant balancing act — creating energy while trying not to burn itself out in the process. Glutathione is the molecule that helps keep that balance. Think of it as the body’s in-house repair team: it finds unstable, harmful molecules (called free radicals), calms them down before they can cause damage, and then recycles other antioxidants so they can keep working too (Kim et al., 2021).

The brain depends on this system more than almost any other organ. It uses vast amounts of oxygen, which means it naturally produces more oxidative “exhaust”. Under normal circumstances, glutathione mops that up before it causes trouble. But in conditions such as Alzheimer’s, Parkinson’s, and ALS, this clean-up system starts to falter (Kim et al., 2021; Chen et al., 2022).

Brain scans show that people with Alzheimer’s disease have noticeably lower levels of glutathione compared with healthy adults (Chen et al., 2022). In ALS, the recycling process that usually restores glutathione appears to slow down, leaving neurons exposed to damage (Kim et al., 2021). And in Parkinson’s disease, glutathione levels drop early — right in the brain’s dopamine-producing centre — before large numbers of cells begin to die (Riederer et al., 2019). That early decline suggests it could be part of the cause, not just a symptom.

In recent years, new brain-imaging tools have given researchers a clearer window into what’s happening. Using magnetic resonance spectroscopy, scientists can measure glutathione inside the living human brain. These studies show that healthy people generally maintain stable levels, but glutathione becomes more fragile when the body is under stress from inflammation, illness, or toxins (Deelchand et al., 2016; Shukla et al., 2018). Scientists describe it as a dynamic buffer — constantly shifting to keep our internal chemistry stable (Rae, 2017).

In Alzheimer’s disease, areas of low glutathione often overlap with regions where excess iron builds up — a bit like metal rusting faster when it’s damp. Together, the two create a perfect storm of oxidative stress (Mandal et al., 2022). Over time, this can wear down neurones’ natural defences, leaving them more vulnerable to inflammation and degeneration.

Laboratory studies help explain why. When scientists switched off the gene that allows neurones to make glutathione, the result was dramatic: the cells became inflamed and died off quickly (Wakida, Mikoshiba & Ono, 2024. Human imaging studies tell a similar story — people with lower brain glutathione tend to have more amyloid-β plaque build-up and faster memory decline (González-Escamilla et al., 2024).

It’s a reminder that these diseases don’t begin overnight — they build slowly, often silently, as the brain’s natural shield begins to weaken. So, if the defences can fail, can we help rebuild them?

Can we rebuild the brain’s defences?

Liposomal Glutathione: Promise and Proof

If glutathione sits at the heart of the body’s defence network, the next question becomes: can we boost it?

In practice, it’s not that simple. Ordinary oral glutathione doesn’t absorb well because the digestive system breaks it down before much can reach the bloodstream (Park et al., 2018). To get around this, scientists developed liposomal glutathione, which wraps the molecule in tiny fat bubbles to protect it during digestion and improve absorption.

Early research suggests that oral glutathione can raise blood levels, and liposomal forms may enhance this effect (Park et al., 2018). However, nearly all of this research has been done in healthy adults. Whether these increases reach the brain or influence neurological conditions remains unknown. Liposomal glutathione seems to safely boost the body's overall antioxidant stores — but its ability to protect the brain itself is still an open question.

Intravenous glutathione: direct delivery, uncertain benefit

Some clinicians have explored intravenous (IV) glutathione, which delivers the compound straight into the bloodstream. It’s an appealing idea — bypass digestion and flood the body with antioxidants — but the science remains mixed.

In ALS, an early controlled trial found no difference in disease progression compared with placebo (Tandan et al., 1996), and later reviews confirmed that neither glutathione nor acetyl cysteine produced meaningful benefit in small follow-up studies (ALS Untangled Group, 2020). In Parkinson’s disease, a pilot double-blind trial showed brief improvements in movement that faded once treatment stopped (Hauser et al., 2009).

More recent analysis suggests that IV glutathione might even create excessively high levels in the blood, which could briefly throw the body out of balance — a phenomenon called reductive stress (Chirumbolo, 2025). New delivery routes, such as intranasal glutathione, are now being studied in a Phase IIb Parkinson’s trial (ClinicalTrials.gov Identifier: NCT02424708), but no current treatment has shown proven disease-modifying effects.

Given under professional supervision, IV glutathione appears safe, but for now it remains experimental — more of a hopeful idea than an established therapy.

Precursors and cofactors: feeding the factory

That is where precursors come in. N-acetylcysteine (NAC) has earned the most attention. NAC provides cysteine, the raw ingredient the body needs to make glutathione. When oxidative stress rises, cysteine often runs short. Human studies show that NAC can raise both blood and brain glutathione, and in a small Parkinson’s trial, it was linked with measurable increases in brain glutathione and modest improvements in movement (Monti et al., 2019). Reviews combining human and laboratory data back up its neuroprotective potential (Tardiolo, Bramanti & Mazzon, 2018).

Another ally is sulforaphane, a compound found in broccoli and other cruciferous vegetables. It activates the body’s “master switch” for antioxidant defence — the Nrf2 pathway — encouraging cells to make and recycle more of their own glutathione (Houghton, Fassett & Coombes, 2019).

Minerals and vitamins quietly support this machinery. Selenium powers glutathione peroxidase, the enzyme that uses glutathione to neutralise harmful peroxides. Without enough selenium, this detox step slows down (Rayman, 2012). Vitamins B2 and B6, and magnesium, help the enzymes that keep the system running smoothly by supporting glutathione recycling and synthesis (Pinto et al., 2009; Ueland et al., 2017; Nielsen, 2018).

Other nutrients add extra reinforcement. Alpha-lipoic acid (ALA) both recycles oxidised glutathione and acts as a strong antioxidant in its own right. Small human trials show it can reduce oxidative stress and support nerve health (El-Sayed et al., 2021). Glycine, one of glutathione’s three building blocks, has also shown promise: when combined with cysteine precursors in older adults, it helped restore redox balance and improved mitochondrial function (Kumar et al., 2021; Sekhar et al., 2022).

Rather than forcing more glutathione into the body, these approaches help it make and reuse its own — nature’s preferred path of restoration over replacement.

Efficacy and safety: what the science really says

Across all approaches, one message stands out: we can raise blood glutathione, but proving that these increases protect or restore the brain is another challenge entirely. Liposomal and intravenous forms improve delivery; nutrients such as NAC, sulforaphane, selenium, ALA, and glycine support the body’s own synthesis. Everyday habits — a nutrient-rich diet, restful sleep, and moderate coffee consumption — provide further support.

At nutritional doses, these strategies appear safe and may strengthen the body’s overall antioxidant capacity. What remains uncertain is whether increasing glutathione can directly slow or reverse diseases like ALS, Parkinson’s, or dementia. Early studies show small but encouraging improvements in oxidative-stress markers or symptoms (Monti et al., 2019; Tardiolo et al., 2018), yet large-scale trials are still needed.

Promisingly, new clinical work is under way. A current human study is investigating whether γ-glutamylcysteine (GGC) — a compound one step before glutathione in its natural production pathway — can raise brain glutathione and improve function in Parkinson’s disease (ClinicalTrials.gov Identifier: NCT07064005).

So far, the evidence supports hopeful caution. Glutathione-focused approaches may not be a cure, but they remain a promising way to enhance resilience, protect cells, and help the brain cope better with stress as research continues to evolve.

Hope without hype

The story of glutathione and brain health is one of both promise and patience. Scientists agree that low glutathione is a consistent sign of brain stress, and restoring it may one day become part of a broader therapeutic strategy. But for now, it’s not a quick fix — it’s about supporting the body’s natural repair systems.

At You Nutrition Clinic, we help clients translate this growing science into safe, personalised nutrition strategies. Whether that means supporting the nutrients that feed glutathione production, improving detoxification, or building a diet rich in natural antioxidants, our goal is always the same: to turn complex science into practical, evidence-based care.

Because when it comes to protecting the brain, informed action — taken one step at a time — is the most powerful path forward.

💬 Stay Connected

If you’d like to explore evidence-based nutrition strategies to support brain health, oxidative balance, and healthy ageing, contact You Nutrition Clinic to speak with one of our practitioners.

🧩 Connect with us

For research updates, practical tips, and ongoing inspiration, follow us on Instagram:

👉 @nutritionandthebrain

Stay curious. Stay hopeful. Support your brain. 🧠

References

Chen, J. J., et al. (2022). Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: A meta-analysis. Alzheimer’s Research & Therapy, 14, 141.

Chirumbolo, S. (2025). Potential paradoxical effects of intravenous antioxidant therapy: Reductive stress and clinical implications. Comptes Rendus Biologies, 348(2), 45–52.

Deelchand, D. K., et al. (2016). Sensitivity and specificity of human brain glutathione concentrations using short-TE ¹H MRS at 7 T. NMR in Biomedicine, 29(5), 600–606.

El-Sayed, A. A., et al. (2021). Alpha-lipoic acid as an antioxidant in neurodegenerative diseases: A systematic review. Clinical Nutrition ESPEN, 41, 26–34.

Esposito, F., Morisco, F., Verde, V., Ritieni, A., Alezio, A., Caporaso, N., & Fogliano, V. (2003). Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. Alimentary Pharmacology & Therapeutics, 17(4), 595–601.

González-Escamilla, G., et al. (2024). Brain glutathione levels, amyloid load, and cognitive performance in ageing and Alzheimer’s disease. Neurobiology of Ageing, 139, 91–99.

Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009). Randomised, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Movement Disorders, 24(7), 979–983.

Holt, S., et al. (2016). The safety and efficacy of coffee enemas: A review. South African Medical Journal, 106(3), 232–234.

Houghton, C. A., Fassett, R. G., & Coombes, J. S. (2019). Sulforaphane: Its ‘coming of age’ as a clinically relevant nutraceutical. Journal of Nutrition & Intermediary Metabolism, 17, 100094.

Kim, K., et al. (2021). Glutathione in the nervous system as a potential therapeutic target in ALS. Antioxidants (Basel), 10(7), 1152.

Kumar, P., Liu, C., Hsu, J. W., Chacko, S., Minard, C., Jahoor, F., & Sekhar, R. V. (2021). GlyNAC supplementation in older adults improves glutathione deficiency and multiple ageing hallmarks: Pilot clinical trial. Clinical and Translational Medicine, 11(3), e372.

Mandal, P. K., et al. (2022). Hippocampal glutathione depletion and iron accumulation in Alzheimer’s disease: A magnetic-resonance study. Brain Communications, 4(5), fcac215.

Monti, D. A., et al. (2019). N-acetyl cysteine is associated with increases in brain glutathione and improved clinical outcomes in Parkinson’s disease. Clinical Pharmacology & Therapeutics, 106(3), 884–890.

Peechakara, B. V. (2024). Riboflavin (Vitamin B₂). In StatPearls [Internet]. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK525977/

Rayman, M. P. (2012). Selenium and human health. The Lancet, 379(9822), 1256–1268.

Rae, C. D. (2017). Glutathione in the human brain: Review of its roles and metabolism. Brain Research Bulletin, 133, 12–18.

Riederer, P., Sofic, E., & Rausch, W. D. (2019). Early changes of reduced glutathione in the substantia nigra of Parkinson’s disease. Journal of Neural Transmission, 126(3), 413–420.

Shukla, D., Mandal, P. K., et al. (2018). A multi-centre study on human brain glutathione conformation using magnetic resonance spectroscopy. Journal of Alzheimer’s Disease, 66(2), 517–532.

Tandan, R., Lewis, R. A., Krusinski, P. B., & Siskind, C. (1996). Controlled trial of glutathione in amyotrophic lateral sclerosis: No evidence of therapeutic effect. Neurology, 47(2), 398–404.

Tardiolo, G., Bramanti, P., & Mazzon, E. (2018). Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Oxidative Medicine and Cellular Longevity, 2018, 1834019.

Ueland, P. M., et al. (2017). Biological and clinical implications of B-vitamins in relation to one-carbon metabolism. American Journal of Clinical Nutrition, 106(6), 1473–1489.

Wakida, N. M., Mikoshiba, K., & Ono, K. (2024). Neuronal glutathione deficiency induces neurodegeneration and inflammation in mice. Scientific Reports, 14, 2746. [Mechanistic]